Medicure Inc. (MPH.V)

1.0200 -0.0700 (-6.42%) At close: 02:49PM EDT

Medicure Inc.

2-1250 Waverley Street
Winnipeg, MB R3T 6C6
Canada
204 487 7412
https://www.medicure.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Neil Owens Ph.D.	President & COO	205k	N/A	N/A
Dr. Reuben Saba Ph.D.	Vice President of Scientific & Medical Affairs	151k	N/A	N/A
Dr. Albert David Friesen Ph.D.	Founder, CEO & Chairman of the board	237.6k	N/A	1947
Mr. Haaris Uddin B.Com., CPA	Chief Financial Officer	60.62k	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

Corporate Governance

Medicure Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.